Cantor Fitzgerald initiated coverage of Eli Lilly (LLY) with an Overweight rating and $975 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo submits obesity pill for FDA approval, BioPharma Dive reports
- Eli Lilly & Co: Strong Market Position and Growth Potential with Orforglipron Launch
- Stock Market Recap: Eli Lilly Soars, UnitedHealth Crashes, Financials Lead Sector Gains
- Eli Lilly’s Stock Soars Amid Promising Drug Trials
- Eli Lilly (LLY) Pledges to Manufacture Weight-Loss Pill in the U.S.